The role of the Organoid Core (Core E) is to generate a bank of state-of-the-art next-generation 3D in vitro organoid models of prostate cancer and provide them to the SPORE research projects for investigation. The study of castration-resistant prostate cancer (CRPC) has been limited by lack of in vitro models that represent the molecular and phenotypic diversity of the disease. We have developed optimized growth conditions for 3D prostate organoids from benign human and mouse prostate epithelial cells that can be engineered with defined genetic lesions using patient-derived CRPC biopsy specimens. The organoids maintain the histology and 3D architecture of the cancer tissue. We have generated 17 CRPC organoid lines over the past 2 years that harbor a number of genetic alterations not present in publicly available cell line models. Leveraging our program?s commitment to collect, annotate, and sequence biopsy specimens from >2000 patients with CRPC, we plan to establish 20 clinically and molecularly annotated CRPC organoid lines annually. We will collaborate with each research project to engineer and study CRPC organoids that harbor specific genetic alterations or molecular phenotypes, including those with mutations in the DNA repair pathway (RP-1), mutations in the PI3K pathway (RP-2), mutations in TP35, silencing of RB1, and/or altered lineage specification (RP-3), and overexpression of different glucocorticoid receptor isoforms (RP-4). Working with the Animal Models Core (Core D), we will generate murine prostate organoids from genetically engineered mouse models harboring the specific genetic alterations of interest for the research projects. We will work with each project to develop protocols for in vitro drug treatment, in vivo xenograft studies, and genetic engineering of the organoid lines such as RNAi-mediated knockdown and CRISPR (clustered regularly interspaced palindromic repeats)-mediated somatic knockout. We will also conduct independent research aimed at improving services, including further optimization of organoid acquisition and growth protocols, identification of clinical and molecular determinants of successful organoid growth, and development of protocols to engineer genetic lesions into benign human prostate organoids.

Public Health Relevance

The study of castration-resistant prostate cancer (CRPC) has been limited by lack of tissue resources and in vitro models. The Organoid Core (Core E) will generate a bank of prostate cancer organoid lines from biopsy specimens of patients with CRPC and distribute them to each research project for study.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Specialized Center (P50)
Project #
Application #
Study Section
Special Emphasis Panel (ZCA1)
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Sloan-Kettering Institute for Cancer Research
New York
United States
Zip Code
Settleman, Jeffrey; Sawyers, Charles L; Hunter, Tony (2018) Challenges in validating candidate therapeutic targets in cancer. Elife 7:
Miyazawa, Miki; Subbaramaiah, Kotha; Bhardwaj, Priya et al. (2018) Pioglitazone Inhibits Periprostatic White Adipose Tissue Inflammation in Obese Mice. Cancer Prev Res (Phila) 11:215-226
Graham, Laura; Banda, Kalyan; Torres, Alba et al. (2018) A phase II study of the dual mTOR inhibitor MLN0128 in patients with metastatic castration resistant prostate cancer. Invest New Drugs 36:458-467
Roobol, Monique J; Carlsson, Sigrid V (2018) The ERSPC Study: Quality Takes Time and Perseverance. Clin Chem :
Shoag, Jonathan; Liu, Deli; Blattner, Mirjam et al. (2018) SPOP mutation drives prostate neoplasia without stabilizing oncogenic transcription factor ERG. J Clin Invest 128:381-386
Van Calster, Ben; Wynants, Laure; Verbeek, Jan F M et al. (2018) Reporting and Interpreting Decision Curve Analysis: A Guide for Investigators. Eur Urol 74:796-804
Mikropoulos, Christos; Selkirk, Christina G Hutten; Saya, Sibel et al. (2018) Prostate-specific antigen velocity in a prospective prostate cancer screening study of men with genetic predisposition. Br J Cancer 118:266-276
Frånlund, Maria; Arnsrud Godtman, Rebecka; Carlsson, Sigrid V et al. (2018) Prostate cancer risk assessment in men with an initial P.S.A. below 3?ng/mL: results from the Göteborg randomized population-based prostate cancer screening trial. Scand J Urol 52:256-262
Lee, Justin K; Sjoberg, Daniel D; Miller, Mariam Imnadze et al. (2018) Improved Recovery of Erectile Function in Younger Men after Radical Prostatectomy: Does it Justify Immediate Surgery in Low-risk Patients? Eur Urol 73:33-37
Capogrosso, Paolo; Vertosick, Emily A; Benfante, Nicole E et al. (2018) Are We Improving Erectile Function Recovery After Radical Prostatectomy? Analysis of Patients Treated over the Last Decade. Eur Urol :

Showing the most recent 10 out of 505 publications